Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.

Pulsipher MA, Langholz B, Wall DA, Schultz KR, Bunin N, Carroll WL, Raetz E, Gardner S, Gastier-Foster JM, Howrie D, Goyal RK, Douglas JG, Borowitz M, Barnes Y, Teachey DT, Taylor C, Grupp SA.

Blood. 2014 Mar 27;123(13):2017-25. doi: 10.1182/blood-2013-10-534297. Epub 2014 Feb 4.

PMID:
24497539
[PubMed - indexed for MEDLINE]
2.

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.

Ho VT, Aldridge J, Kim HT, Cutler C, Koreth J, Armand P, Antin JH, Soiffer RJ, Alyea EP.

Biol Blood Marrow Transplant. 2009 Jul;15(7):844-50. doi: 10.1016/j.bbmt.2009.03.017.

PMID:
19539216
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).

Pulsipher MA, Wall DA, Grimley M, Goyal RK, Boucher KM, Hankins P, Grupp SA, Bunin N.

Br J Haematol. 2009 Dec;147(5):691-9. doi: 10.1111/j.1365-2141.2009.07889.x. Epub 2009 Sep 10.

PMID:
19744131
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.

Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK, Wood L, Abdelqader S, Schwartz J, Srivastava S, Abonour R, Robertson MJ, Nelson RP Jr, Cornetta K, Fausel CA, Farag SS.

Biol Blood Marrow Transplant. 2011 Jun;17(6):916-22. doi: 10.1016/j.bbmt.2010.09.017. Epub 2010 Dec 4.

PMID:
20932925
[PubMed - indexed for MEDLINE]
5.

Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.

Alyea EP, Li S, Kim HT, Cutler C, Ho V, Soiffer RJ, Antin JH.

Biol Blood Marrow Transplant. 2008 Aug;14(8):920-6. doi: 10.1016/j.bbmt.2008.05.024.

PMID:
18640576
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.

Shayani S, Palmer J, Stiller T, Liu X, Thomas SH, Khuu T, Parker PM, Khaled SK, Forman SJ, Nakamura R.

Biol Blood Marrow Transplant. 2013 Feb;19(2):298-304. doi: 10.1016/j.bbmt.2012.10.006. Epub 2012 Oct 15.

PMID:
23078784
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.

Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, Fisher DC, Miklos D, Levin J, Sonis S, Soiffer RJ, Antin JH.

Biol Blood Marrow Transplant. 2004 May;10(5):328-36.

PMID:
15111932
[PubMed - indexed for MEDLINE]
8.

Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis.

Snyder DS, Palmer J, Gaal K, Stein AS, Pullarkat V, Sahebi F, Vora N, Nakamura R, Forman SJ.

Biol Blood Marrow Transplant. 2010 Feb;16(2):281-6. doi: 10.1016/j.bbmt.2009.09.020. Epub 2009 Sep 26.

PMID:
19786111
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.

Ringdén O, Remberger M, Dahllöf G, Garming-Legert K, Karlsson H, Svenberg P, Uhlin M, Uzunel M, Mattsson J.

Eur J Haematol. 2011 Dec;87(6):503-9. doi: 10.1111/j.1600-0609.2011.01685.x. Epub 2011 Oct 2.

PMID:
22974354
[PubMed - indexed for MEDLINE]
10.

Cord blood transplantation from unrelated donors for children with acute lymphoblastic leukemia in Japan: the impact of methotrexate on clinical outcomes.

Kato K, Yoshimi A, Ito E, Oki K, Hara J, Nagatoshi Y, Kikuchi A, Kobayashi R, Nagamura-Inoue T, Kai S, Azuma H, Takanashi M, Isoyama K, Kato S; Japan Cord Blood Bank Network.

Biol Blood Marrow Transplant. 2011 Dec;17(12):1814-21. doi: 10.1016/j.bbmt.2011.05.013. Epub 2011 May 25.

PMID:
21664471
[PubMed - indexed for MEDLINE]
11.

Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation.

Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, Antin JH.

Blood. 2007 Apr 1;109(7):3108-14.

PMID:
17138818
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.

Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR.

Blood. 1998 Oct 1;92(7):2303-14.

PMID:
9746768
[PubMed - indexed for MEDLINE]
Free Article
13.

Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.

Kim HJ, Min WS, Cho BS, Eom KS, Kim YJ, Min CK, Lee S, Cho SG, Jin JY, Lee JW, Kim CC.

Biol Blood Marrow Transplant. 2009 Jun;15(6):704-17. doi: 10.1016/j.bbmt.2009.02.010. Epub 2009 Apr 9.

PMID:
19450755
[PubMed - indexed for MEDLINE]
14.

A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.

Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G, Garvin J, George D, Bradley MB, Wolownik K, Wischhover C, Levy J, Skerrett D, Cairo MS.

Biol Blood Marrow Transplant. 2004 Apr;10(4):246-58.

PMID:
15077223
[PubMed - indexed for MEDLINE]
15.

The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.

Perez-Simón JA, Martino R, Parody R, Cabrero M, Lopez-Corral L, Valcarcel D, Martinez C, Solano C, Vazquez L, Márquez-Malaver FJ, Sierra J, Caballero D.

Haematologica. 2013 Apr;98(4):526-32. doi: 10.3324/haematol.2012.065599. Epub 2012 Oct 12.

PMID:
23065527
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, Przepiorka D, Davies S, Petersen FB, Bartels P, Buell D, Fitzsimmons W, Anasetti C, Storb R, Ratanatharathorn V.

Blood. 2000 Sep 15;96(6):2062-8.

PMID:
10979948
[PubMed - indexed for MEDLINE]
Free Article
17.

Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.

Sabry W, Le Blanc R, Labbé AC, Sauvageau G, Couban S, Kiss T, Busque L, Cohen S, Lachance S, Roy DC, Roy J.

Biol Blood Marrow Transplant. 2009 Aug;15(8):919-29. doi: 10.1016/j.bbmt.2009.04.004. Epub 2009 Jun 10.

PMID:
19589481
[PubMed - indexed for MEDLINE]
18.

Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.

Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R.

Blood. 2008 Dec 1;112(12):4425-31. doi: 10.1182/blood-2008-07-169342. Epub 2008 Sep 5.

PMID:
18776081
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Tacrolimus as monotherapy or combined with minidose methotrexate for graft-versus-host disease prophylaxis after allogeneic peripheral blood stem cell transplantation: long-term outcomes.

Uberti JP, Ayash L, Braun T, Reynolds C, Silver S, Ratanatharathorn V.

Bone Marrow Transplant. 2004 Sep;34(5):425-31.

PMID:
15273705
[PubMed - indexed for MEDLINE]
20.

Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.

Mori T, Kato J, Shimizu T, Aisa Y, Nakazato T, Yamane A, Ono Y, Kunimoto H, Okamoto S.

Biol Blood Marrow Transplant. 2012 Feb;18(2):229-34. doi: 10.1016/j.bbmt.2011.06.008. Epub 2011 Jun 25.

PMID:
21708109
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk